{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:52:09Z","timestamp":1765615929082,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,13]]},"DOI":"10.7759\/cureus.99090","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:49:21Z","timestamp":1765615761000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrated Assessment of Drugs and Interventional Devices in the Management of Acute Myocardial Infarction, Refractory Angina, and Heart Failure: A Clinical Outcome-Based Study"],"prefix":"10.7759","author":[{"given":"Farhan","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Safa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazila","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameel","family":"Gandikota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.559751","article-title":"Global, regional, and national death, and disability-adjusted life-years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the Global Burden of Disease study and implications for prevention","volume":"9","author":"Li Z","year":"2021","unstructured":"Li Z, Lin L, Wu H, Yan L, Wang H, Yang H, Li H. Global, regional, and national death, and disability-adjusted life-years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the Global Burden of Disease study and implications for prevention. Front Public Health. 2021, 9:559751. 10.3389\/fpubh.2021.559751","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-2517-9_1","article-title":"Coronary artery disease: from mechanism to clinical practice","volume":"1177","author":"Shao C","year":"2020","unstructured":"Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol. 2020, 1177:1-36. 10.1007\/978-981-15-2517-9_1","journal-title":"Adv Exp Med Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/09638288.2020.1817984","article-title":"Barriers to accessing primary healthcare services for people with disabilities in low and middle-income countries, a meta-synthesis of qualitative studies","volume":"44","author":"Hashemi G","year":"2022","unstructured":"Hashemi G, Wickenden M, Bright T, Kuper H. Barriers to accessing primary healthcare services for people with disabilities in low and middle-income countries, a meta-synthesis of qualitative studies. Disabil Rehabil. 2022, 44:1207-20. 10.1080\/09638288.2020.1817984","journal-title":"Disabil Rehabil"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.002","article-title":"The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology","volume":"60","author":"Laslett LJ","year":"2012","unstructured":"Laslett LJ, Alagona P Jr, Clark BA 3rd, et al.. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012, 60:S1-49. 10.1016\/j.jacc.2012.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications","volume":"120","author":"Mensah GA","year":"2017","unstructured":"Mensah GA, Wei GS, Sorlie PD, et al.. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017, 120:366-80. 10.1161\/CIRCRESAHA.116.309115","journal-title":"Circ Res"},{"key":"ref6","article-title":"Acculturation, coronary artery disease and carotid intima media thickness in South Asian immigrants--unique population with increased risk","volume":"21","author":"Dodani S","year":"2011","unstructured":"Dodani S, Dong L. Acculturation, coronary artery disease and carotid intima media thickness in South Asian immigrants--unique population with increased risk. Ethn Dis. 2011, 21:314-21.","journal-title":"Ethn Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302804","article-title":"Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon","volume":"114","author":"Soukoulis V","year":"2014","unstructured":"Soukoulis V, Boden WE, Smith SC Jr, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res. 2014, 114:1944-58. 10.1161\/CIRCRESAHA.114.302804","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2016.87","article-title":"Network biology concepts in complex disease comorbidities","volume":"17","author":"Hu JX","year":"2016","unstructured":"Hu JX, Thomas CE, Brunak S. Network biology concepts in complex disease comorbidities. Nat Rev Genet. 2016, 17:615-29. 10.1038\/nrg.2016.87","journal-title":"Nat Rev Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.783290","article-title":"Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up","volume":"118","author":"Valham F","year":"2008","unstructured":"Valham F, Mooe T, Rabben T, Stenlund H, Wiklund U, Franklin KA. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation. 2008, 118:955-60. 10.1161\/CIRCULATIONAHA.108.783290","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-024-01165-2","article-title":"Pharmacologic management of heart failure with preserved ejection fraction (HFpEF) in older adults","volume":"42","author":"Hashemi A","year":"2025","unstructured":"Hashemi A, Kwak MJ, Goyal P. Pharmacologic management of heart failure with preserved ejection fraction (HFpEF) in older adults. Drugs Aging. 2025, 42:95-110. 10.1007\/s40266-024-01165-2","journal-title":"Drugs Aging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2021-0058","article-title":"Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina","volume":"18","author":"Tamargo J","year":"2022","unstructured":"Tamargo J, Lopez-Sendon J. Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiol. 2022, 18:235-51. 10.2217\/fca-2021-0058","journal-title":"Future Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281718","article-title":"Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review","volume":"310","author":"Deb S","year":"2013","unstructured":"Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. JAMA. 2013, 310:2086-95. 10.1001\/jama.2013.281718","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.062","article-title":"Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial","volume":"55","author":"Maron DJ","year":"2010","unstructured":"Maron DJ, Boden WE, O'Rourke RA, et al.. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010, 55:1348-58. 10.1016\/j.jacc.2009.10.062","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-124013","article-title":"Lessons learned from the ISCHEMIA trial for the management of patients with stable ischemic heart disease","volume":"74","author":"Boden WE","year":"2023","unstructured":"Boden WE, Stone PH. Lessons learned from the ISCHEMIA trial for the management of patients with stable ischemic heart disease. Annu Rev Med. 2023, 74:189-98. 10.1146\/annurev-med-042921-124013","journal-title":"Annu Rev Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli M","year":"2021","unstructured":"Valgimigli M, Frigoli E, Heg D, et al.. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021, 385:1643-55. 10.1056\/NEJMoa2108749","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa1060","article-title":"The year in cardiovascular medicine 2020: valvular heart disease","volume":"42","author":"Bermejo J","year":"2021","unstructured":"Bermejo J, Postigo A, Baumgartner H. The year in cardiovascular medicine 2020: valvular heart disease. Eur Heart J. 2021, 42:647-56. 10.1093\/eurheartj\/ehaa1060","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018830","article-title":"National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator","volume":"133","author":"Lindvall C","year":"2016","unstructured":"Lindvall C, Chatterjee NA, Chang Y, Chernack B, Jackson VA, Singh JP, Metlay JP. National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Circulation. 2016, 133:273-81. 10.1161\/CIRCULATIONAHA.115.018830","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004042","article-title":"Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study","volume":"129","author":"Moran AE","year":"2014","unstructured":"Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, Naghavi M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014, 129:1483-92. 10.1161\/CIRCULATIONAHA.113.004042","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf S","year":"2020","unstructured":"Yusuf S, Joseph P, Rangarajan S, et al.. Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020, 395:795-808. 10.1016\/S0140-6736(19)32008-2","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.19082\/6383","article-title":"Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study","volume":"10","author":"Farshidi H","year":"2018","unstructured":"Farshidi H, Abdi A, Madani A, Moshiri S, Ghasemi A, Hakimian R. Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study. Electron Physician. 2018, 10:6383-9. 10.19082\/6383","journal-title":"Electron Physician"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000763","article-title":"Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials","volume":"5","author":"Champs B","year":"2019","unstructured":"Champs B, Degbo\u00e9 Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD Open. 2019, 5:e000763. 10.1136\/rmdopen-2018-000763","journal-title":"RMD Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.6515\/ACS.201905_35(3).20190422A","article-title":"2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure","volume":"35","author":"Wang CC","year":"2019","unstructured":"Wang CC, Wu CK, Tsai ML, et al.. 2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure. Acta Cardiol Sin. 2019, 35:244-83. 10.6515\/ACS.201905_35(3).20190422A","journal-title":"Acta Cardiol Sin"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.010","article-title":"Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction","volume":"70","author":"Givertz MM","year":"2017","unstructured":"Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, Abraham WT. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017, 70:1875-86. 10.1016\/j.jacc.2017.08.010","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247641","article-title":"Multimodality imaging in advanced heart failure for diagnosis, management and follow-up: a comprehensive review","volume":"12","author":"Pergola V","year":"2023","unstructured":"Pergola V, Cameli M, Mattesi G, et al.. Multimodality imaging in advanced heart failure for diagnosis, management and follow-up: a comprehensive review. J Clin Med. 2023, 12:10.3390\/jcm12247641","journal-title":"J Clin Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2012.04.026","article-title":"Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations","volume":"9","author":"Linde C","year":"2012","unstructured":"Linde C, Ellenbogen K, McAlister FA. Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations. Heart Rhythm. 2012, 9:S3-S13. 10.1016\/j.hrthm.2012.04.026","journal-title":"Heart Rhythm"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"Angermann CE","year":"2020","unstructured":"Angermann CE, Assmus B, Anker SD, et al.. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail. 2020, 22:1891-901. 10.1002\/ejhf.1943","journal-title":"Eur J Heart Fail"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2025.01","article-title":"Device-based strategies for monitoring congestion and guideline-directed therapy in heart failure: the who, when and how of personalised care","volume":"11","author":"Laborante R","year":"2025","unstructured":"Laborante R, Restivo A, Mele D, et al.. Device-based strategies for monitoring congestion and guideline-directed therapy in heart failure: the who, when and how of personalised care. Card Fail Rev. 2025, 11:e11. 10.15420\/cfr.2025.01","journal-title":"Card Fail Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euac039","article-title":"The MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy","volume":"24","author":"Dauw J","year":"2022","unstructured":"Dauw J, Martens P, Nijst P, et al.. The MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy. Europace. 2022, 24:1276-83. 10.1093\/europace\/euac039","journal-title":"Europace"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12023","article-title":"Clinical characteristics, mortality, cardiac hospitalization, and ventricular arrhythmias in patients undergoing CRT-D implantation: results of the ACTION-HF study","volume":"24","author":"Botto GL","year":"2013","unstructured":"Botto GL, Dicandia CD, Mantica M, et al.. Clinical characteristics, mortality, cardiac hospitalization, and ventricular arrhythmias in patients undergoing CRT-D implantation: results of the ACTION-HF study. J Cardiovasc Electrophysiol. 2013, 24:173-81. 10.1111\/jce.12023","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399463-integrated-assessment-of-drugs-and-interventional-devices-in-the-management-of-acute-myocardial-infarction-refractory-angina-and-heart-failure-a-clinical-outcome-based-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:49:22Z","timestamp":1765615762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399463-integrated-assessment-of-drugs-and-interventional-devices-in-the-management-of-acute-myocardial-infarction-refractory-angina-and-heart-failure-a-clinical-outcome-based-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.99090","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,13]]}}}